HEALTH CARE:
PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
Tekmira Pharmaceuticals Corporation a biopharmaceutical company develops and commercializes proprietary drugs and drug delivery systems for the treatment of cancer and other diseases.
| Market Cap | 262.053 Million | Shares Outstanding | 68.961 Million | Avg 30-day Volume | 15.985 Million |
| P/E Ratio | Dividend Yield | EPS | -2.67 | ||
| Price/Sales | 42.472 | Price cash flow ratio | 7665.1 | Price free cash flow ratio | -5.0 |
| Book Value | -0.97 | Price to Tangible Book | -3.91 | Alpha | -0.0 |
| Short Interest Ratio | % Short Interest to Float | R-squared | 0.218074 | ||
| BETA | 3.14316 | 52-week High/Low | 9.02 / 0.8214 | Stddev | 0.283035 |
| Q1 2020 | All Institutions | Hedge Funds 1 |
|---|---|---|
| Filers who had this stock in their top 10: | 0 | 0 (0.0%) |
| 13F Filers holding this stock: | 48 | 18 (1.18%) |
| Aggregate 13F shares on 03/31/2020: | 28.059 Million | 14.113 Million |
| Aggregate 13F shares on 12/31/2019: | 24.263 Million | 13.192 Million |
| Percent change: | 15.65% | 6.98% |
| Funds creating new positions: | 9 | 5 |
| Funds Adding to an existing position: | 18 | 7 |
| Funds closing out their position: | 18 | 8 |
| Funds reducing their position: | 10 | 4 |
| 1 hedge funds as identified by whalewisdom.com through public filings. | ||
| Arbutus Biopharma Corp Chart by YCharts | |
| Yahoo! Finance | finviz |
| SEC Web Site | SEC DEF 14A Filings |
Please sign in first
none
20 Thousand total shares from 1 transactions
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
KOWALSKI MARK CHIEF MEDICAL OFFICER |
|
0 | 2020-08-12 | 0 |
|
53,500 | 2020-07-29 | 2 | |
|
MCELHAUGH MICHAEL J. CHIEF BUSINESS OFFICER |
|
1,367,457 | 2020-07-23 | 2 |
|
10,000 | 2020-07-21 | 0 | |
|
21,480 | 2020-07-21 | 1 | |
|
0 | 2020-07-06 | 1 | |
|
4,454,566 | 2020-06-23 | 0 | |
|
0 | 2020-06-23 | 0 | |
|
0 | 2020-06-23 | 0 | |
|
0 | 2020-06-17 | 2 | |
|
0 | 2020-05-28 | 0 | |
|
0 | 2020-05-28 | 2 | |
|
0 | 2020-05-28 | 2 | |
|
0 | 2020-05-28 | 2 | |
|
COLLIER WILLIAM H. PRESIDENT AND CEO |
|
0 | 2020-05-28 | 2 |
|
0 | 2020-05-28 | 3 | |
|
47,213,419 | 2020-05-12 | 0 | |
|
0 | 2020-05-05 | 0 | |
|
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC |
|
33,333,333 | 2020-04-28 | 0 |
|
0 | 2020-02-18 | 1 | |
|
SOFIA MICHAEL J. CHIEF SCIENTIFIC OFFICER |
|
0 | 2020-02-17 | 1 |
|
HOWARD ELIZABETH CHIEF COMPLIANCE OFFICER |
|
0 | 2020-02-17 | 1 |
|
PICCHIO GASTON CHIEF DEVELOPMENT OFFICER |
|
0 | 2020-02-17 | 1 |
|
0 | 2019-07-10 | 0 | |
|
0 | 2019-07-10 | 0 | |
|
0 | 2019-07-10 | 0 | |
|
0 | 2019-07-10 | 0 | |
|
MURRAY MARK J. PRESIDENT AND CEO |
|
0 | 2019-03-01 | 0 |
|
22,703,669 | 2019-01-01 | 0 | |
|
VANDENENDEN KOERT CHIEF ACCOUNTING OFFICER |
|
0 | 2018-12-11 | 0 |
|
22,703,669 | 2018-10-01 | 0 | |
|
0 | 2018-06-19 | 0 | |
|
SYMONDS WILLIAM T. CHIEF DEVELOPMENT OFFICER |
|
0 | 2018-04-16 | 0 |
|
LUTWYCHE PETER FORMER CHIEF TECH. OFFICER |
|
No longer subject to file | 2018-04-11 | 0 |
|
COUSINS BRUCE EXEC VO & CFO |
|
No longer subject to file | 2018-02-16 | 0 |
|
16,013,540 | 2017-09-06 | 0 | |
|
75,000,000 | 2017-07-01 | 0 | |
|
37,231,342 | 2016-10-26 | 0 | |
|
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC |
|
37,231,342 | 2016-10-26 | 0 |
|
ABRAMS MICHAEL J. MANAGING DIRECTOR |
|
No longer subject to file | 2016-09-30 | 0 |
|
HIGGINS PATRICK T. CHIEF BUSINESS OFFICER |
|
No longer subject to file | 2016-04-30 | 0 |
|
No longer subject to file | 2015-03-04 | 0 | |
|
No longer subject to file | 2015-03-04 | 0 | |
|
BRENNAN PAUL A. SR VP, BUSINESS DEVELOPMENT |
|
No longer subject to file | 2015-03-04 | 0 |
| Reporting Owners | Transaction Date | Transaction Code | Shares | Share Price | Acquired or Disposed | Shares Owned Following Transaction | Combined shares owned after filing | Direct/Indirect Ownership | 10b-5 |
|---|---|---|---|---|---|---|---|---|---|
| 2020-07-23 | S | 20,000 | $5.01 | d | 1,367,457 | 1,367,457.00 | direct | yes |
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
